The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway

Conclusion: Maytenus compound significantly inhibited the proliferation of HCC cells in vitro and in vivo. The downregulation of the EGFR-PI3K-AKT signaling pathway and subsequent inhibition of cell cycle progression from G1 to S phase is one of the possible mechanisms. Maytenus compound has a high tumor growth inhibition rate and has no obvious organ toxicity, which may make it a potential anti-HCC drug, but the results from this study need to be confirmed by further clinical trials in HCC patients.

Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Wen-Tao Zhao, Liu-Xin Han, Lin Liu, Bao-Zhen Zeng, Yi Zhang, Liu-Fang Zhao, Hong-Yan Hu, Jia-Wei Xia, Yi-Ze Li, Xu-Dong Xiang, Xiao-Lin Lin, Di Lu, Gao-Feng Li Tags: Research Paper Source Type: research